CME and CMLE credits are not available for this course.
Description:Cytogenetic evaluation of AML and MDS has been the mainstay of clinical risk assessment for over 40 years. While effective for risk-stratification, cytogenetics requires the culture of live cells and provides limited resolution to resolve complex genomic events. Whole genome sequencing, WGS, is capable of unbiased genomic evaluation from DNA but has been considered too expensive and too complicated, for clinical use. In this webinar we will discuss recent advances that have made WGS feasible in the clinical setting, how WGS data can be used for the comprehensive genomic assessment of AML and MDS patients, and how WGS could be implemented for the evaluation of other cancer types.
Learning Objectives:
- Describe how cytogenetics and molecular testing plays a role in the diagnosis and management of myeloid disorders such as AML.
- Identify key barriers to using whole genome sequencing (WGS) in the clinical setting.
- Describe benefits of WGS over conventional genomic testing in myeloid malignancies.
- Identify other areas of molecular diagnostics where WGS could be applied.
 |
 |
|---|---|
| Speaker: Eric Duncavage, MD Washington University School of Medicine |
Moderator: Nathanael G. Bailey, MD Chair, T&E Committee University of Pittsburgh Medical Center |
Level of Instruction: Basic
Recording Date: July 20, 2021
Continuing Education Credit Information
CME and CMLE credits are not available for this course.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
